SCHEMBL4893124

SCHEMBL4893124

CC(=O)Nc1nc(C=Cc2ccc(CC(=O)O)n2C)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
HSD17B10 Q99714 2/20 0.49
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
TYR P14679 1/20 0.38
DHFR P00374 3/20 0.37
EGFR P00533 3/20 0.37
ABL1 P00519 2/20 0.37
MAPK1 P28482 1/20 0.37
AOC3 Q16853 3/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CASP3 P42574 1/20 0.36
HTT P42858 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893118 1.00 KDM4E (0.49) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4892315 0.77 KDM4E (0.48) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4892309 0.77 KDM4E (0.48) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3943822 0.77 KDM4E (0.50) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3930858 0.77 KDM4E (0.50) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL3930854 0.77 KDM4E (0.50) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4886281 0.76 AOC3 (0.55) L3MBTL1SMN1; SMN2KMT2ANPC1RAB9A
SCHEMBL970756 0.73 HSD17B10 (0.46) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL970755 0.73 HSD17B10 (0.46) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2
SCHEMBL4883834 0.71 KDM4E (0.61) KDM4EHSD17B10MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity ASTELLAS PHARMA INC. (JP) 2008-01-17 US disclosed
EP-1791835-A2 THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY Astellas Pharma Inc. (JP) 2007-06-06 EP disclosed
WO-2006028269-A2 THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY ASTELLAS PHARMA INC. (JP) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015202-A1 Thiazole Derivatives Having Vap-1 Inhibitory Activity VCAM1, VAPB, VAPA KDM4E 3463/4885HSD17B10 1895/4885MAPT 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.